Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.

He-Rui Yao Min YanZhongsheng TongXinhong WuMin-Hee Ryu John J Park Jee Hyun KimYahua ZhongYiming ZhaoMark VoskoboynikYongmei YinKan LiuAndreas KaubischCaigang LiuJian ZhangShouman WangSeock-Ah Im Vinod GanjuMinal BarveHui LiChangsheng YeAmitesh C RoyLi-Yuan BaiChia-Jui YenShanzhi GuYung-Chang Lin Ling-Ying WuLequn BaoKaijing ZhaoYu ShenShangyi RongXiaoyu ZhuErwei Song

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

SHR-A1811 exhibited acceptable tolerability, promising antitumor activity, and a favorable pharmacokinetic profile in heavily pretreated advanced solid tumors. The recommended phase II dose of 4.8 or 6.4 mg/kg was selected for various tumor types.

Keyphrases

epidermal growth factor receptor
phase ii
tyrosine kinase
advanced non small cell lung cancer
open label
endothelial cells
clinical trial
phase iii
pluripotent stem cells
study protocol
placebo controlled
double blind